Literature DB >> 32502247

Inverse Association Between Chronic Hepatitis B Infection and Coronavirus Disease 2019 (COVID-19): Immune Exhaustion or Coincidence?

Chimaobi M Anugwom1,2, Elizabeth S Aby1,2, Jose D Debes1,2,3.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 32502247      PMCID: PMC7314123          DOI: 10.1093/cid/ciaa592

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
To the Editor—We read with great interest the report by Zhao et al, regarding a case of delayed immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a patient with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection [1]. The authors stipulate that previous HIV and HCV infection could confer immune dysfunction providing a differential immune response during coronavirus disease 2019 (COVID-19) development. This report, as most initial reports, originated in China, which has an intermediate-high prevalence of chronic hepatitis B (HBV) infection [2]. We evaluated all peer-reviewed articles, written in the English language, reporting cases of COVID-19 infection and specifically defining rates of HBV infection and hospital admission, since 1 December 2019 until 25 March 2020 and found a surprisingly low prevalence of chronic HBV in COVID-19 cases admitted to the hospital. Indeed, Of the 2054 cases that were reported with this information, only 28 patients (1.36%) were reported positive for HBV. Several of these studies reported 0% incidence of HBV among individuals infected with COVID-19. We matched the HBV rates in COVID-19 subjects to age-specific rates of HBV reported in the respective geographic areas of origin (Table 1). The median age of COVID-19 infected individuals in the evaluated studies ranged between 47 and 51 years, corresponding to HBV rates ranging from 7% to 11%, whereas the HBV rates of those with COVID-19 remained between 0% and 1.3%. It is unclear whether this is a simple epidemiological “misconnection” or if being chronically infected with HBV impacts the chances of clinically significant infection with SARS-CoV-2 leading to fewer hospital admissions, in a similar fashion as that reported by Zhao et al to HIV and HCV. In this regard, research has documented that chronic HBV infection leads to a reduced or absent virus-specific T-cell reactivity (although HBV-specific T cells). This phenomenon, known as “immune exhaustion,” is manifested by an impaired ability of T-lymphocytes to produce appropriate cytokines secondary to years of continuous, yet inefficient, immune reaction to the virus [3]. Immune exhaustion is also frequently observed in chronic HCV infection [4]. In this setting, it is plausible that the exhaustion of T lymphocytes may affect their ability to respond to other viruses and reduce the degree of “cytokine storm” that has been noticed in COVID-19 patients, thus culminating in a less severe disease. Similar patterns of immune cointeraction with consequences in clinical presentation and prognosis have been reported in individuals infected with HBV and schistosomiasis [5]. Further research is needed to elucidate if this epidemiological outlier is a consequence of immune dysregulation or just coincidence. If it is indeed the former, it could provide important insights in to the immunopathology of COVID-19 and open potentially unique venues for prevention and treatment.
Table 1.

Rates of Hepatitis B Infection Among Patients With Coronavirus Disease 2019 and the General Population by Region and Age Group

StudyRegion StudiedNo. of PatientsAge Group of COVID-19 Patients, y, median (IQR)No. of Patients With HBVHepatitis B Rate, %
COVID-19 PatientsRegionSimilar Age Group in Region
Zhao et al [6]Anhui, China1948 (27–56)15.267.447.5–9a
Guan et al [7]China109947 (35–58)232.16.89~5.5–7a
Chen et al [8]Wuhan, China9955.5 (36–64)006.89b~5.5–7b
Xu et al [9]cWuhan, China6241 (32–52)23.226.89b~5.5–7b
Chen et al [10]Shanghai, China24951 (36–64)20.87.28.3–8.7a
Young et al [11]cSingapore1847 (31–71)003.6~4.1a
Pan et al (in press)Hubei, China20452.9 (SD, 16)009.211.1a

Abbreviations: COVID-19, coronavirus disease 2019; HBV, hepatitis B virus; SD, standard deviation.

aLi et al. [12]; Wang et al. [13]; Ji et al. [14]; Ang et al. [15]; She et al. [16].

bNo data specific to the Wuhan area were noted and so general rates in China were used here.

cPersonal communication from the authors.

Rates of Hepatitis B Infection Among Patients With Coronavirus Disease 2019 and the General Population by Region and Age Group Abbreviations: COVID-19, coronavirus disease 2019; HBV, hepatitis B virus; SD, standard deviation. aLi et al. [12]; Wang et al. [13]; Ji et al. [14]; Ang et al. [15]; She et al. [16]. bNo data specific to the Wuhan area were noted and so general rates in China were used here. cPersonal communication from the authors.
  14 in total

Review 1.  The Path to Cancer and Back: Immune Modulation During Hepatitis C Virus Infection, Progression to Fibrosis and Cancer, and Unexpected Roles of New Antivirals.

Authors:  Jose D Debes; Robert J de Knegt; Andre Boonstra
Journal:  Transplantation       Date:  2017-05       Impact factor: 4.939

2.  Seroepidemiology of hepatitis B virus infection among adults in Singapore: a 12-year review.

Authors:  Li Wei Ang; Jeffery Cutter; Lyn James; Kee Tai Goh
Journal:  Vaccine       Date:  2013-11-05       Impact factor: 3.641

3.  Hepatitis B virus infections and risk factors among the general population in Anhui Province, China: an epidemiological study.

Authors:  Xiaoqing Li; Yingjun Zheng; Adrian Liau; Biao Cai; Dongqing Ye; Feng Huang; Xiaorong Sheng; Fuyang Ge; Liu Xuan; Shun Li; Jing Li
Journal:  BMC Public Health       Date:  2012-04-05       Impact factor: 3.295

4.  A seroepidemiologic study of hepatitis B virus infection among barbers in Huangshi City, Hubei, China.

Authors:  S L She; L Y Shi; Y J Wu; Z Z Li; C Z Zheng; Y P Wu; X H Yu
Journal:  Microbiol Immunol       Date:  1988       Impact factor: 1.955

5.  Hepatitis B infection in the general population of China: a systematic review and meta-analysis.

Authors:  Huai Wang; Peixuan Men; Yufeng Xiao; Pei Gao; Min Lv; Qianli Yuan; Weixin Chen; Shuang Bai; Jiang Wu
Journal:  BMC Infect Dis       Date:  2019-09-18       Impact factor: 3.090

6.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.

Authors:  Xiao-Wei Xu; Xiao-Xin Wu; Xian-Gao Jiang; Kai-Jin Xu; Ling-Jun Ying; Chun-Lian Ma; Shi-Bo Li; Hua-Ying Wang; Sheng Zhang; Hai-Nv Gao; Ji-Fang Sheng; Hong-Liu Cai; Yun-Qing Qiu; Lan-Juan Li
Journal:  BMJ       Date:  2020-02-19

7.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

8.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

9.  A population-based study examining hepatitis B virus infection and immunization rates in Northwest China.

Authors:  Zhaohua Ji; Tingcai Wang; Zhongjun Shao; Dahong Huang; Anhui Wang; Zhiwen Guo; Yong Long; Lei Zhang; Haixia Su; Qi Zhang; Yongping Yan; Daiming Fan
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

10.  Clinical progression of patients with COVID-19 in Shanghai, China.

Authors:  Jun Chen; Tangkai Qi; Li Liu; Yun Ling; Zhiping Qian; Tao Li; Feng Li; Qingnian Xu; Yuyi Zhang; Shuibao Xu; Zhigang Song; Yigang Zeng; Yinzhong Shen; Yuxin Shi; Tongyu Zhu; Hongzhou Lu
Journal:  J Infect       Date:  2020-03-19       Impact factor: 6.072

View more
  9 in total

Review 1.  HBV coinfection and in-hospital outcomes for COVID-19: a systematic review and meta-analysis.

Authors:  Julie H Zhu; Kevork M Peltekian
Journal:  Can Liver J       Date:  2021-02-24

Review 2.  Molecular, Viral and Clinical Features of Alcohol- and Non-Alcohol-Induced Liver Injury.

Authors:  Manuela G Neuman; Helmut K Seitz; Rolf Teschke; Stephen Malnick; Kamisha L Johnson-Davis; Lawrence B Cohen; Anit German; Nicolas Hohmann; Bernhardo Moreira; George Moussa; Mihai Opris
Journal:  Curr Issues Mol Biol       Date:  2022-03-16       Impact factor: 2.976

3.  First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India.

Authors:  Tenzin Tsundue; Tenzin Namdon; Tenzin Tsewang; Sonam Topgyal; Tashi Dolma; Dekyi Lhadon; Tsering Choetso; Tenzin Woesal; Tenzin Yangkyi; Amita Gupta; David Peters; Zorba Paster; Dawa Phunkyi; Tsetan Dorji Sadutshang; Richard E Chaisson; Kunchok Dorjee
Journal:  BMJ Glob Health       Date:  2022-05

4.  Association of liver abnormalities with in-hospital mortality in patients with COVID-19.

Authors:  Ze-Yang Ding; Gan-Xun Li; Lin Chen; Chang Shu; Jia Song; Wei Wang; Yu-Wei Wang; Qian Chen; Guan-Nan Jin; Tong-Tong Liu; Jun-Nan Liang; Peng Zhu; Wei Zhu; Yong Li; Bin-Hao Zhang; Huan Feng; Wan-Guang Zhang; Zhen-Yu Yin; Wen-Kui Yu; Yang Yang; Hua-Qiu Zhang; Zhou-Ping Tang; Hui Wang; Jun-Bo Hu; Ji-Hong Liu; Ping Yin; Xiao-Ping Chen; Bixiang Zhang
Journal:  J Hepatol       Date:  2020-12-19       Impact factor: 25.083

Review 5.  Interaction between hepatitis B virus and SARS-CoV-2 infections.

Authors:  Tian-Dan Xiang; Xin Zheng
Journal:  World J Gastroenterol       Date:  2021-03-07       Impact factor: 5.742

Review 6.  Impact of COVID-19 on liver disease: From the experimental to the clinic perspective.

Authors:  Sheila Gato; Ana Lucena-Valera; Rocío Muñoz-Hernández; José Manuel Sousa; Manuel Romero-Gómez; Javier Ampuero
Journal:  World J Virol       Date:  2021-11-25

Review 7.  Care of the Hepatology Patient in the COVID-19 Era.

Authors:  Kathryn E Driggers; Brett W Sadowski; Eva Shagla; Ryan M Kwok
Journal:  Curr Hepatol Rep       Date:  2022-04-01

8.  Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis.

Authors:  Yang Yu; Xingzhao Li; Taihu Wan
Journal:  Dig Dis Sci       Date:  2022-09-09       Impact factor: 3.487

Review 9.  Viral coinfections in COVID-19.

Authors:  Parisa S Aghbash; Narges Eslami; Milad Shirvaliloo; Hossein B Baghi
Journal:  J Med Virol       Date:  2021-06-12       Impact factor: 20.693

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.